Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.

Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C.

Leukemia. 2019 Jun 10. doi: 10.1038/s41375-019-0505-x. [Epub ahead of print]

PMID:
31182782
2.

Position of Scientific Oncological Societies Towards Biosimilar Antibodies.

Wörmann B, Sinn M.

Breast Care (Basel). 2019 Mar;14(1):5-8. doi: 10.1159/000495145. Epub 2019 Jan 15. Review.

3.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.

Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.

4.

[Diagnosis and Therapy of Immune thrombocytopenia].

Matzdorff A, Wörmann B.

Dtsch Med Wochenschr. 2018 Aug;143(15):1076-1081. doi: 10.1055/a-0384-4703. Epub 2018 Jul 30. Review. German.

PMID:
30060276
5.

Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis.

Bokemeyer C, Busse R, Engel J, Gebauer A, Hallek M, Heinemann V, Lüftner D, Wörmann B.

Oncol Res Treat. 2018;41 Suppl 3:2-26. doi: 10.1159/000490082. Epub 2018 Jul 26. No abstract available.

6.

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.

Hornung R, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Amler S, Sauerland MC, Berdel WE, Wörmann BJ, Bohlander SK, Braess J, Hiddemann W, Lehmann S, Mareschal S, Spiekermann K, Metzeler KH, Herold T, Boulesteix AL.

Sci Rep. 2018 Jul 26;8(1):11293. doi: 10.1038/s41598-018-29593-2.

7.

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.

Schranz K, Hubmann M, Harin E, Vosberg S, Herold T, Metzeler KH, Rothenberg-Thurley M, Janke H, Bräundl K, Ksienzyk B, Batcha AMN, Schaaf S, Schneider S, Bohlander SK, Görlich D, Berdel WE, Wörmann BJ, Braess J, Krebs S, Hiddemann W, Mansmann U, Spiekermann K, Greif PA.

Oncotarget. 2018 Jul 10;9(53):30128-30145. doi: 10.18632/oncotarget.25729. eCollection 2018 Jul 10.

8.

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.

Haematologica. 2018 Nov;103(11):1853-1861. doi: 10.3324/haematol.2018.191536. Epub 2018 Jun 14.

9.

Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.

Greif PA, Hartmann L, Vosberg S, Stief SM, Mattes R, Hellmann I, Metzeler KH, Herold T, Bamopoulos SA, Kerbs P, Jurinovic V, Schumacher D, Pastore F, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Graf A, Krebs S, Blum H, Neumann M, Baldus CD, Bohlander SK, Wolf S, Görlich D, Berdel WE, Wörmann BJ, Hiddemann W, Spiekermann K.

Clin Cancer Res. 2018 Apr 1;24(7):1716-1726. doi: 10.1158/1078-0432.CCR-17-2344. Epub 2018 Jan 12.

10.

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.

Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K.

Haematologica. 2018 Mar;103(3):456-465. doi: 10.3324/haematol.2017.178442. Epub 2017 Dec 14.

11.

Late Effects and Long-Term Follow-Up after Cancer in Childhood.

Langer T, Grabow D, Steinmann D, Wörmann B, Calaminus G.

Oncol Res Treat. 2017;40(12):746-750. doi: 10.1159/000484936. Epub 2017 Nov 29. Review.

12.

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.

Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4.

PMID:
29114972
13.

Supportive Treatments for Patients with Cancer.

Jordan K, Feyer P, Höller U, Link H, Wörmann B, Jahn F.

Dtsch Arztebl Int. 2017 Jul 10;114(27-28):481-487. doi: 10.3238/arztebl.2017.0481. Review.

14.

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE.

Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4.

PMID:
28674423
15.

The Treatment of Hepatitis C- An Introduction to the Use of New Medicines.

Wörmann B.

Dtsch Arztebl Int. 2017 Jan 9;114(1-02):9-10. doi: 10.3238/arztebl.2017.0009. No abstract available.

16.

Breast cancer: basics, screening, diagnostics and treatment.

Wörmann B.

Med Monatsschr Pharm. 2017 Feb;40(2):55-64. Review. English, German.

PMID:
29952495
17.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
18.

Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia.

Laverdière I, Boileau M, Herold T, Rak J, Berdel WE, Wörmann B, Hiddemann W, Spiekermann K, Bohlander SK, Eppert K.

Exp Hematol. 2016 Nov;44(11):1039-1043.e10. doi: 10.1016/j.exphem.2016.07.012. Epub 2016 Jul 26.

PMID:
27473565
19.

Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.

Herold T, Metzeler KH, Vosberg S, Hartmann L, Jurinovic V, Opatz S, Konstandin NP, Schneider S, Zellmeier E, Ksienzyk B, Graf A, Krebs S, Blum H, Cristina Sauerland M, Büchner T, Berdel WE, Wörmann BJ, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, Greif PA.

Genes Chromosomes Cancer. 2017 Jan;56(1):75-86. doi: 10.1002/gcc.22418. Epub 2016 Oct 25.

PMID:
27636548
20.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K; AMLCG Study Group.

Blood. 2016 Aug 4;128(5):686-98. doi: 10.1182/blood-2016-01-693879. Epub 2016 Jun 10.

21.

ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.

Hartmann L, Dutta S, Opatz S, Vosberg S, Reiter K, Leubolt G, Metzeler KH, Herold T, Bamopoulos SA, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Hopfner KP, Graf A, Krebs S, Blum H, Middeke JM, Stölzel F, Thiede C, Wolf S, Bohlander SK, Preiss C, Chen-Wichmann L, Wichmann C, Sauerland MC, Büchner T, Berdel WE, Wörmann BJ, Braess J, Hiddemann W, Spiekermann K, Greif PA.

Nat Commun. 2016 Jun 2;7:11733. doi: 10.1038/ncomms11733.

22.

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.

Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W.

Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. No abstract available.

PMID:
26965440
23.

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.

Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9.

PMID:
26859081
24.

[Future requirements for oncological care: Challenges due to demographic change].

Wörmann B.

Urologe A. 2015 Dec;54(12):1725-30. doi: 10.1007/s00120-015-4007-9. Review. German.

PMID:
26704275
25.

RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.

Lichtenegger FS, Kondla I, Krempasky M, Weber AL, Herold T, Krupka C, Spiekermann K, Schneider S, Büchner T, Berdel WE, Wörmann BJ, Hiddemann W, Subklewe M.

Cancer Immunol Immunother. 2015 Dec;64(12):1505-15. doi: 10.1007/s00262-015-1755-8. Epub 2015 Sep 16.

PMID:
26377688
26.

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.

Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Büchner T, Wörmann B, Hiddemann W, Berdel WE, Brümmendorf TH, Müller-Tidow C, Koschmieder S.

PLoS One. 2015 May 21;10(5):e0125783. doi: 10.1371/journal.pone.0125783. eCollection 2015.

27.

New drug for the treatment of inoperable pancreatic cancer?

Wörmann B.

Dtsch Arztebl Int. 2015 Jan 5;112(1-2):10. doi: 10.3238/arztebl.2015.0010a. No abstract available.

28.

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H.

Eur J Cancer. 2015 Jan;51(1):27-36. doi: 10.1016/j.ejca.2014.10.010. Epub 2014 Nov 5.

PMID:
25459392
29.

Benefits and risks of cervical cancer screening.

Petry KU, Wörmann B, Schneider A.

Oncol Res Treat. 2014;37 Suppl 3:48-57. doi: 10.1159/000365059. Epub 2014 Aug 29. No abstract available.

30.

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.

Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10.

PMID:
24912430
31.

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.

Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K.

Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. Epub 2014 May 9.

32.

[Immune thrombocytopenia -- onkopedic guidelines update: recommendations of a joint working group of the DGHO, ÖGHO, SGH + SSH and GPOH].

Matzdorff A, Eberl W, Giagounidis A, Imbach P, Pabinger I, Wörmann B.

Oncol Res Treat. 2014;37 Suppl 2:6-25. doi: 10.1159/000356910. German. No abstract available.

33.

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, Cervantes A, Casali PG, Sessa C, Van Cutsem E, de Vries E, Pavlidis N, Fumasoli K, Wörmann B, Samonigg H, Cascinu S, Cruz Hernández JJ, Howard AJ, Ciardiello F, Stahel RA, Piccart M.

Ann Oncol. 2014 Jan;25(1):9-15. doi: 10.1093/annonc/mdt522. Epub 2013 Dec 13. Erratum in: Ann Oncol. 2014 Apr;25(4):916.

34.

Clinical indications for thrombopoietin and thrombopoietin-receptor agonists.

Wörmann B.

Transfus Med Hemother. 2013 Oct;40(5):319-25. doi: 10.1159/000355006. Epub 2013 Sep 11. Review.

35.

[Diagnosis of and therapy for hepatocellular carcinoma].

Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ.

Z Gastroenterol. 2013 Nov;51(11):1269-326. doi: 10.1055/s-0033-1355841. Epub 2013 Nov 15. German.

36.

Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.

Fiegl M, Unterhalt M, Kern W, Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Schöndube D, Serve H, Reichle A, Hentrich M, Schiel X, Sauerland C, Heinecke A, Rieger C, Beelen D, Berdel WE, Büchner T, Hiddemann W; German AML Cooperative Group (AMLCG).

Leukemia. 2014 May;28(5):1001-7. doi: 10.1038/leu.2013.297. Epub 2013 Oct 22.

PMID:
24150216
37.

[New drugs in oncology: benefits, risks and challenges].

Cella D, Vervölgyi V, Wörmann B.

Onkologie. 2013;36 Suppl 5:12-9. doi: 10.1159/000352000. Epub 2013 Jul 1. German. No abstract available.

38.

[Status of clinical trials in oncology--2013 and onwards].

Wörmann B, Freund M, Overkamp F, Ehninger G.

Onkologie. 2013;36 Suppl 2:3-8. doi: 10.1159/000348257. German.

39.

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.

Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Ann Hematol. 2013 Jan;92(1):41-52. doi: 10.1007/s00277-012-1597-9. Epub 2012 Oct 23.

40.

[Foreword].

Wörmann B.

Onkologie. 2012;35 Suppl 5:2. Epub 2012 Aug 10. German. No abstract available.

PMID:
22965287
41.

The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.

Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Kakadia PM, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Heinecke A, Sauerland MC, Berdel WE, Büchner T, Wörmann BJ, Hiddemann W, Spiekermann K.

Blood. 2012 May 10;119(19):4383-6. doi: 10.1182/blood-2010-12-327072. Epub 2012 Feb 28.

42.

Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.

Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group.

Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24.

PMID:
22362118
43.

[Venous thrombembolism in tumour patients].

Pabinger I, Alt-Epping B, Demarmels Biasutti F, Langer F, Wörmann B, Riess H.

Hamostaseologie. 2011 Nov;31(4):281-90; quiz 291-2. doi: 10.5482/ha-1174. Epub 2011 Oct 10. German.

PMID:
21983992
44.

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance Leukemia Investigators.

Lancet. 2010 Dec 11;376(9757):2000-8. doi: 10.1016/S0140-6736(10)62105-8. Epub 2010 Dec 3.

PMID:
21131036
45.

[Oncology 2010].

Wörmann B.

Dtsch Med Wochenschr. 2010 Jun;135(25-26):1339-40. doi: 10.1055/s-0030-1255167. Epub 2010 Jun 16. Review. German. No abstract available.

PMID:
20556695
46.

[Systemic treatment of metastatic prostate cancer].

Wörmann B, Wolff JM.

Urologe A. 2010 Feb;49(2):221-7. doi: 10.1007/s00120-010-2238-3. Review. German.

PMID:
20180063
47.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
48.

Efficient generation of clinical-grade genetically modified dendritic cells for presentation of multiple tumor-associated proteins.

Garritsen HS, Macke L, Meyring W, Hannig H, Pägelow U, Wörmann B, Geffers R, Dittmar KE, Lindenmaier W.

Transfusion. 2010 Apr;50(4):831-42. doi: 10.1111/j.1537-2995.2009.02519.x. Epub 2009 Dec 10.

PMID:
20003055
49.

Evaluating maturation and genetic modification of human dendritic cells in a new polyolefin cell culture bag system.

Macke L, Garritsen HS, Meyring W, Hannig H, Pägelow U, Wörmann B, Piechaczek C, Geffers R, Rohde M, Lindenmaier W, Dittmar KE.

Transfusion. 2010 Apr;50(4):843-55. doi: 10.1111/j.1537-2995.2009.02520.x. Epub 2009 Dec 10.

PMID:
20003054
50.

ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.

Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A, Berdel WE, Büchner T, Wörmann B, Mansmann U, Braess J, Spiekermann K, Hiddemann W, Buske C, Bohlander SK.

J Clin Oncol. 2009 Oct 20;27(30):5031-8. doi: 10.1200/JCO.2008.20.5328. Epub 2009 Sep 14.

PMID:
19752345

Supplemental Content

Loading ...
Support Center